WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015
- 1 May 2017
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 61 (5), e00072-17
- https://doi.org/10.1128/aac.00072-17
Abstract
WCK 5222 consists of cefepime combined with zidebactam, a bicyclo-acyl hydrazide β-lactam enhancer antibiotic with a dual action involving binding to Gram-negative bacterial PBP2 and β-lactamase inhibition. We evaluated the in vitro activity of cefepime-zidebactam against 7,876 contemporary (2015) clinical isolates of Enterobacteriaceae ( n = 5,946), Pseudomonas aeruginosa ( n = 1,291), and Acinetobacter spp. ( n = 639) from the United States ( n = 2,919), Europe ( n = 3,004), the Asia-Pacific ( n = 1,370), and Latin America ( n = 583). The isolates were tested by a reference broth microdilution method for susceptibility against cefepime-zidebactam (1:1 and 2:1 ratios) and comparator agents. Cefepime-zidebactam was the most active compound tested against Enterobacteriaceae (MIC 50/90 , ≤0.03/0.12 μg/ml [1:1] and 0.06/0.25 μg/ml [2:1]; 99.9% of isolates were inhibited at ≤4 [1:1] and ≤8 μg/ml [2:1]). Cefepime-zidebactam was active against individual Enterobacteriaceae species (MIC 50/90 , ≤0.03 to 0.06/≤0.03 to 0.5 μg/ml [1:1]) and retained potent activity against carbapenem-resistant isolates (MIC 50/90 , 1/4 μg/ml; 99.3% of isolates were inhibited at ≤8 μg/ml [1:1]). Cefepime-zidebactam activity was consistent among geographic regions, and only one isolate showed MIC values of >8 μg/ml (1:1). Cefepime-zidebactam was also very active against P. aeruginosa with MIC 50/90 values of 1/4 μg/ml, and 99.5% of isolates were inhibited at ≤8 μg/ml (1:1). The MIC values for cefepime-zidebactam at the 1:1 ratio were generally 2-fold lower than those for cefepime-zidebactam at the 2:1 ratio (MIC 50/90 , 2/8 μg/ml) and zidebactam alone (MIC 50/90 , 4/8 μg/ml). Against Acinetobacter spp., cefepime-zidebactam at 1:1 and 2:1 ratios (MIC 50/90 , 16/32 μg/ml for both) was 4-fold more active than cefepime or ceftazidime. Zidebactam exhibited potent in vitro antimicrobial activity against some organisms. These results support the clinical development of WCK 5222 for the treatment of Gram-negative bacterial infections, including those caused by multidrug-resistant isolates.This publication has 16 references indexed in Scilit:
- Determining a clinical framework for use of cefepime and -lactam/ -lactamase inhibitors in the treatment of infections caused by extended-spectrum- -lactamase-producing EnterobacteriaceaeJournal of Antimicrobial Chemotherapy, 2013
- Regional Resistance Surveillance Program Results for 12 Asia-Pacific Nations (2011)Antimicrobial Agents and Chemotherapy, 2013
- Prevalence of β-Lactamase-Encoding Genes among Enterobacteriaceae Bacteremia Isolates Collected in 26 U.S. Hospitals: Report from the SENTRY Antimicrobial Surveillance Program (2010)Antimicrobial Agents and Chemotherapy, 2013
- 10 x '20 Progress--Development of New Drugs Active Against Gram-Negative Bacilli: An Update From the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2013
- Proliferation and significance of clinically relevant β‐lactamasesAnnals of the New York Academy of Sciences, 2013
- Background and Rationale for Revised Clinical and Laboratory Standards Institute Interpretive Criteria (Breakpoints) for Enterobacteriaceae andPseudomonas aeruginosa:I. Cephalosporins and AztreonamClinical Infectious Diseases, 2013
- Multiresistant Gram-negative bacteria: the role of high-risk clones in the dissemination of antibiotic resistanceFEMS Microbiology Reviews, 2011
- Cefepime: a reappraisal in an era of increasing antimicrobial resistanceExpert Review of Anti-infective Therapy, 2008
- Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998–2003)Diagnostic Microbiology and Infectious Disease, 2005
- CefepimeDrugs, 1994